Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 0.99
23.8 %
$ 15.3 M
Market Cap
None
P/E
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.[ Read More ]
The intrinsic value of one BIAFW stock under the base case scenario is HIDDEN Compared to the current market price of 0.99 USD, bioAffinity Technologies, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart BIAFW
FINANCIALS
2.53 M
REVENUE
-7.97 M
OPERATING INCOME
-7.94 M
NET INCOME
-6.04 M
OPERATING CASH FLOW
-2.21 M
INVESTING CASH FLOW
-345 K
FINANCING CASH FLOW
2.35 M
REVENUE
-1.97 M
OPERATING INCOME
-2 M
NET INCOME
-1.71 M
OPERATING CASH FLOW
-9.41 K
INVESTING CASH FLOW
1.67 M
FINANCING CASH FLOW
Balance Sheet Decomposition
bioAffinity Technologies, Inc.
| Current Assets | 3.97 M |
| Cash & Short-Term Investments | 2.82 M |
| Receivables | 812 K |
| Other Current Assets | 340 K |
| Non-Current Assets | 4.25 M |
| Long-Term Investments | 0 |
| PP&E | 1.99 M |
| Other Non-Current Assets | 2.25 M |
| Current Liabilities | 2.25 M |
| Accounts Payable | 605 K |
| Short-Term Debt | 920 K |
| Other Current Liabilities | 723 K |
| Non-Current Liabilities | 1.12 M |
| Long-Term Debt | 1.12 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
bioAffinity Technologies, Inc.
| Revenue | 2.53 M |
| Cost Of Revenue | 1.74 M |
| Gross Profit | 792 K |
| Operating Expenses | 8.76 M |
| Operating Income | -7.97 M |
| Other Expenses | -36.2 K |
| Net Income | -7.94 M |
RATIOS
31.26%
GROSS MARGIN
-314.84%
OPERATING MARGIN
-313.41%
NET MARGIN
-163.47%
ROE
-96.54%
ROA
-150.40%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
bioAffinity Technologies, Inc.
| Net Income | -7.94 M |
| Depreciation & Amortization | 250 K |
| Capital Expenditures | -22.9 K |
| Stock-Based Compensation | 749 K |
| Change in Working Capital | 901 K |
| Others | 604 K |
| Free Cash Flow | -6.06 M |
Wall Street Analysts Price Targets
bioAffinity Technologies, Inc.
BIAFW has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
bioAffinity Technologies, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
KNIGHT PETER S
Director |
+ 8163
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
KNIGHT PETER S
Director |
+ 8163
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
Anderson Robert A.
Director |
+ 4081
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
DIAMOND STUART
Director |
+ 4081
|
0 USD |
|
2 years ago
Sep 01, 2022
|
Bought 0 USD
|
Edwards James Michael
Chief Financial Officer |
+ 2448
|
0 USD |
|
2 years ago
Sep 01, 2022
|
Bought 0 USD
|
Edwards James Michael
Chief Financial Officer |
+ 2448
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
Zannes Maria
President, CEO |
+ 16326
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
Zannes Maria
President, CEO |
+ 16326
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
GIRGENTI STEVEN
Executive Chairman |
+ 40916
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
GIRGENTI STEVEN
Executive Chairman |
+ 40916
|
0 USD |
|
2 years ago
Sep 06, 2022
|
Bought 0 USD
|
GIRGENTI STEVEN
Executive Chairman |
+ 5952
|
0 USD |
|
2 years ago
Jul 20, 2022
|
Bought 0 USD
|
GIRGENTI STEVEN
Executive Chairman |
+ 2380
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
Rubin Gary D
Director |
+ 16326
|
0 USD |
|
2 years ago
Sep 06, 2022
|
Bought 0 USD
|
Rubin Gary D
Director |
+ 408125
|
0 USD |
|
2 years ago
Jul 20, 2022
|
Bought 0 USD
|
Rubin Gary D
Director |
+ 163248
|
0 USD |
|
2 years ago
Aug 31, 2022
|
Bought 0 USD
|
Rubin Gary D
Director |
+ 16326
|
0 USD |
7. News
8. Profile Summary
bioAffinity Technologies, Inc. BIAFW
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 15.3 M
Dividend Yield
0.00%
Description
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
Contact
http://www.bioaffinitytech.com
IPO Date
None
Employees
75
Officers
Dr. William Bauta Ph.D.
Chief Science Officer
Mr. J. Michael Edwards CPA, M.B.A.
Chief Financial Officer & Principal Accounting Officer
Ms. Julie Anne Overton
Director of Communications
Mr. Dallas J. Coleman
Vice President of sales
Mr. Steven Girgenti
Founder & Executive Chairman of the Board
Ms. Maria Zannes J.D.
Founder, President, Chief Executive Officer & Director
Mr. Xavier T. Reveles M.S.
Chief Operating Officer
Mr. Timothy P. Zannes J.D.
Executive Vice President, Secretary & General Counsel